Harmony Biosciences Holdings, Inc. $HRMY Holdings Boosted by LSV Asset Management

LSV Asset Management raised its position in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 24.6% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,488,502 shares of the company’s stock after purchasing an additional 293,541 shares during the quarter. LSV Asset Management’s holdings in Harmony Biosciences were worth $47,037,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the business. Envestnet Asset Management Inc. grew its holdings in shares of Harmony Biosciences by 8.4% during the first quarter. Envestnet Asset Management Inc. now owns 58,329 shares of the company’s stock valued at $1,936,000 after buying an additional 4,503 shares in the last quarter. Arizona State Retirement System boosted its position in Harmony Biosciences by 6.4% during the 1st quarter. Arizona State Retirement System now owns 12,261 shares of the company’s stock worth $407,000 after acquiring an additional 737 shares during the period. New York State Common Retirement Fund grew its stake in Harmony Biosciences by 6.9% during the 1st quarter. New York State Common Retirement Fund now owns 66,171 shares of the company’s stock valued at $2,196,000 after acquiring an additional 4,293 shares in the last quarter. CWM LLC increased its holdings in shares of Harmony Biosciences by 34.8% in the 1st quarter. CWM LLC now owns 2,704 shares of the company’s stock valued at $90,000 after purchasing an additional 698 shares during the period. Finally, Victory Capital Management Inc. lifted its position in shares of Harmony Biosciences by 44.5% in the first quarter. Victory Capital Management Inc. now owns 211,894 shares of the company’s stock worth $7,033,000 after purchasing an additional 65,285 shares in the last quarter. Hedge funds and other institutional investors own 86.23% of the company’s stock.

Harmony Biosciences Stock Performance

Shares of NASDAQ:HRMY opened at $33.99 on Wednesday. The stock has a market capitalization of $1.96 billion, a PE ratio of 10.69, a P/E/G ratio of 0.44 and a beta of 0.85. Harmony Biosciences Holdings, Inc. has a 1 year low of $25.52 and a 1 year high of $40.93. The firm has a fifty day moving average price of $29.63 and a 200 day moving average price of $32.93. The company has a current ratio of 3.75, a quick ratio of 3.72 and a debt-to-equity ratio of 0.18.

Harmony Biosciences (NASDAQ:HRMY) last posted its earnings results on Tuesday, November 4th. The company reported $0.87 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.05). The company had revenue of $239.46 million for the quarter, compared to the consensus estimate of $222.68 million. Harmony Biosciences had a net margin of 22.50% and a return on equity of 24.88%. Analysts expect that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current fiscal year.

Analyst Ratings Changes

HRMY has been the topic of a number of research analyst reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Harmony Biosciences in a research report on Monday. Mizuho boosted their price target on shares of Harmony Biosciences from $36.00 to $39.00 and gave the company an “outperform” rating in a report on Thursday, November 6th. Wall Street Zen downgraded shares of Harmony Biosciences from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. UBS Group reduced their price objective on Harmony Biosciences from $50.00 to $43.00 and set a “buy” rating for the company in a research report on Wednesday, October 15th. Finally, Deutsche Bank Aktiengesellschaft dropped their target price on Harmony Biosciences from $54.00 to $36.00 and set a “buy” rating on the stock in a research report on Thursday, September 25th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, Harmony Biosciences has a consensus rating of “Moderate Buy” and an average target price of $44.50.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.